Year:2023   Volume: 5   Issue: 2   Area:

  1. Home
  2. Article List
  3. ID: 275

Noha Mohammed SALEH

DETECTION OF GENOMIC MARKERS BY RANDOM AMPLIFIED POLYMORPHIC ‎DNA ANALYSIS IN LEUKEMIA PATIENTS

One of the hematological malignancies brought on by the abnormal proliferation of immature ‎leukocytes is leukemia. Numerous epigenetic and genetic changes in hematopoietic progenitor cells ‎are the cause of it. The Random Amplification of Polymorphic DNA (RAPD) technique has been ‎utilized in the presented work in order to assess DNA polymorphisms and discover genomic markers ‎in diverse leukemia types. The analysis utilizing a random primer regarding decamer ‎oligonucleotides OPJ-04 produced distinct profiles of amplified fragments of DNA in the genomic ‎DNA of 3 different types of the leukemia patients. The unique band (2178 bp), which is present in ‎‎60 and 66.6% of chronic myeloid leukemia (CML) and acute myeloid leukemia (AML), ‎respectively, exhibited a significant difference (P ≤ 0.01). While detected in only 20% of cases ‎chronic lymphoid leukemia (CLL), and absent in the remaining leukemia patients and healthy ‎controls. The results showed that the distinct bands (1737 and 1513 bp), which were present in all ‎leukemia patients, however absent in healthy controls, showed extremely significant differences (P ‎‎≤ 0.01). Similarly, results have revealed highly significant differences (P ≤ 0.010) in fourth distinct ‎band (1202 bp) that detected in all AML, 86.6% of CML, and 90% of CLL, and lacking in the ‎remaining leukemia patients and in all healthy controls The results also showed that there have ‎been significant differences (P ≤ 0.01) in the amplified band (750 bp), which was absent in 73.3% ‎of CML patients, but present in the remaining CML patients, along with all AML patients, CLL ‎patients, and healthy controls. The 4 amplified DNA fragments (1031, 870, 600, and 300 bp) that ‎detected in all healthy controls and leukemia patients, at the same time, showed no significant ‎differences in the results. The recognized DNA polymorphisms through the arbitrary primer OPJ-04 ‎may be used as a genetic marker to design a successful RAPD primer for the diagnosis of leukemia ‎patients‎.

Keywords: Genetic Markers, DNA Polymorphism, Leukemia, RAPD-PCR

http://dx.doi.org/10.47832/2717-8234.15.8


242